Exploring the landscape of targetable alterations in patients with glioblastoma

A comprehensive review in Nature Reviews Clinical Oncology maps the landscape of targetable molecular alterations in glioblastoma and examines why prior targeted therapy approaches have largely failed. The authors identify key challenges, including blood-brain barrier penetrance, intra-tumoral heterogeneity, and redundant signaling pathways, that have limited clinical progress despite advances in other solid tumors. The review highlights emerging strategies such as novel clinical trial designs and next-generation targeted agents that may overcome these barriers and improve patient outcomes.